Cell and gene therapies have emerged as remarkable medical breakthroughs, offering the potential to treat or even cure diseases that were once intractable. But according to a recent opinion piece in MedCity News, these advances are at risk. The problem, the author argues, is not the science but the economics: if we cannot find sustainable ways to pay for these treatments, the pipeline of future therapies will fail.
The piece puts forward what it calls a radical proposal to address this challenge. While the details of the proposal are not fully spelled out in the excerpt, the core argument is clear: the current payment system is not built for one-time, high-cost therapies that may offer lifelong benefits. Without a new approach, developers may abandon promising research, and patients could lose access to future cures.
The author frames the issue as a choice between preserving innovation and letting the system buckle under financial strain. The proposal is described as radical, suggesting it would require significant changes to how treatments are financed and reimbursed. Whether such a plan can gain traction remains an open question, but the piece makes a pointed case that doing nothing is not a viable option.